目次

Table of Contents

1. Introduction
1.1 Therapeutic Monoclonal Antibodies Market Overview
1.2 Scope of Research

2. Executive Summary
2.1 Market Snapshot
2.2 Regional Insights
2.3 Market Ecosystem Factors

3. Research Methodology
3.1 Data Collection Process
3.2 Market Trajectory Estimation
3.3 Market Size Calculation-Top-to-Bottom

4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Trends
4.5 Analyst Recommendations
4.6 Impact Analysis

5. Value Chain Analysis

6. COVID-19 Impact Assessment
6.1 Degree of Impact of COVID-19 on Therapeutic Monoclonal Antibodies Market
6.2 Region-Wise Quarterly Coved Impact Analysis (2020)

7. Porter's five forces analysis

8. Macro Economic Indicator Outlook
8.1 GDP per capita growth (annual %)
8.2 Global Medical Spending
8.3 Current Healthcare Expenditure
8.4 Pharmaceutical Spending/capita

9. Competitive Positioning
9.1 Companies' Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of Therapeutic Monoclonal Antibodies Market
9.4 Company profiles
9.4.1 Eli-Lily & Co
9.4.2 GSK plc.
9.4.3 Bayer AG
9.4.4 Johnson & Johnson
9.4.5 Amgen
9.4.6 Astra Zeneca plc.
9.4.7 Novartis
9.4.8 Merck & Co., Inc.
9.4.9 Pfizer Inc.
9.4.10 Roche Holding AG

10. Global therapeutic monoclonal antibodies market
10.1 Impact Analysis of Macro Economic Factors on Therapeutic Monoclonal Antibodies Market
10.2 Market Size and CAGR
10.3 Global Therapeutic Monoclonal Antibodies Market: Market Value Assessment
10.4 Market Summary

11 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Source
11.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Source: Snapshot
11.2 Humanized
11.3 Murine
11.4 Chimeric
11.5 Human

12. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Target
12.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Target: Snapshot
12.2 Cell surface antigen
12.3 Plasma protein or drug
12.4 Infectious organism
12.5 Other Targets

13. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Indication
13.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
13.2 Cancer
13.3 Infectious Disease
13.4 Autoimmune Disorders
13.5 Neurological Disorders
13.6 Other Indications

14. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Route of Administration
14.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
14.2 Intravenous
14.3 Subcutaneous
14.4 Other ROA

15. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Region
15.1 Regional Coverage of the Study

16. Americas Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
16.1 Macro Economic Factor Impact Index
16.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
16.3 Americas Therapeutic Monoclonal Antibodies Market: Snapshot
16.4 Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
16.5 Americas Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
16.5.1 By Source
16.5.2 By Target
16.5.3 By Indication
16.5.4 By Route of Administration
16.5.5 By Country
16.5.5.1 United States
16.5.5.2 Canada
16.5.5.3 Brazil

17. Europe Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
17.1 Macro Economic Factor Impact Index
17.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
17.3 Europe Therapeutic Monoclonal Antibodies Market: Snapshot
17.4 Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
17.5 Europe Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
17.5.1 By Source
17.5.2 By Target
17.5.3 By Indication
17.5.4 By Route of Administration
17.5.5 By Country
17.5.5.1 Germany
17.5.5.2 United Kingdom
17.5.5.3 France
17.5.5.4 Italy
17.5.5.5 Spain
17.5.5.6 Rest of Europe

18. Asia Pacific Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
18.1 Macro Economic Factor Impact Index
18.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
18.3 Asia Pacific Therapeutic Monoclonal Antibodies Market: Snapshot
18.4 Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
18.5 Asia Pacific Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
18.5.1 By Source
18.5.2 By Target
18.5.3 By Indication
18.5.4 By Route of Administration
18.5.5 By Country
18.5.5.1 China
18.5.5.2 Japan
18.5.5.3 India
18.5.5.4 Rest of Asia Pacific

19. Middle East & Africa Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Million & CAGR
19.1 Macro Economic Factor Impact Index
19.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
19.3 Middle East & Africa Therapeutic Monoclonal Antibodies Market: Snapshot
19.4 Middle East Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Million)
19.5 Middle East & Africa Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
19.5.1 By Source
19.5.2 By Target
19.5.3 By Indication
19.5.4 By Route of Administration

List of Figures
Figure 1: Therapeutic Monoclonal Antibodies Market for next 7 years (in USD Millions)
Figure 2: Therapeutic Monoclonal Antibodies Market Size, By Route of Administration, 2018 & 2028 (USD Million)
Figure 3: Therapeutic Monoclonal Antibodies Market Size by Target, 2021 (%)
Figure 4: Market Share of Prominent Companies of Therapeutic Monoclonal Antibodies, 2021 (%)
Figure 5: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
Figure 6: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 7: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 8: GSK plc. Revenues, 2019-2021 (USD Million)
Figure 9: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 10: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 11: Bayer AG. Revenues, 2019-2021 (USD Million)
Figure 12: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 13: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 14: Johnson & Johnson Revenues, 2019-2021 (USD Million)
Figure 15: J&J Revenue, By Business Segments, 2021 (%)
Figure 16: J&J Revenue, By Business Segments, 2021 (%)
Figure 17: Amgen Pharmaceuticals Revenues, 2019-2021 (USD Million)
Figure 18: Amgen Revenue, By Business Segments, 2021 (%)
Figure 19: Amgen Revenue, By Business Segments, 2020 (%)
Figure 20: Astra Zeneca Revenues, 2019-2021 (USD Million)
Figure 21: Astra Zeneca Revenue, Product Sales by Disease Area, 2021 (%)
Figure 22: Astra Zeneca Revenue, By Geographical Segments, 2021 (%)
Figure 23: Novartis Revenues, 2019-2021 (USD million)
Figure 24: Novartis Revenue, By Business Segments, 2021 (%)
Figure 25: Novartis Revenue, By Business Segments, 2021 (%)
Figure 26: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
Figure 27: Merck & Co., Inc. Revenue, By Geographic segment, 2021 (%)
Figure 28: Merck & Co., Inc. Revenue, By Business Segments, 2021 (%)
Figure 29: Pfizer Inc. Revenues, 2019-2021 (USD Million)
Figure 30: Pfizer Inc. Revenue, By Business Segments- By Products, 2021 (%)
Figure 31: Pfizer Inc. Revenue, By Business Segments, 2021 (%)
Figure 32: Roche Revenues, 2019-2021 (USD Million)
Figure 33: Roche Revenue, By Business Segments- By Products, 2021 (%)
Figure 34: Roche Revenue, By Business Segments, 2021 (%)
Figure 35a: At a CAGR of 18.63% during 2023-2028, the global market value is expected to reach USD 1076.64 billion in 2028
Figure 35b: Value sales of Therapeutic Monoclonal Antibodies is expected to sustain a staggering sale of 1076.64 billion in 2028
Figure 36: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2022,2028)
Figure 37: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2023-2028)
Figure 38: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 39: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 40: Global Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 41: Global Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 42: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 43: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 44: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 45: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 46: Global Humanized Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 47: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 48: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 49: Global Murine Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 50: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 51: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 52: Global Chimeric, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 53: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 54: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 55: Global Human, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 56: Global Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 57: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 58: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 59: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 60: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Figure 61: Global Therapeutic Monoclonal Antibodies Market, By Cell surface antigen, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 62: Global Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or drug, By Value, 2018-2021 (USD Billion)
Figure 63: Global Therapeutic Monoclonal Antibodies Market Size, Plasma protein or drug, By Value, 2022-2028 (USD Billion)
Figure 64: Global Therapeutic Monoclonal Antibodies Market, By Plasma protein or drug, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 65: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2018-2021 (USD Billion)
Figure 66: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2022-2028 (USD Billion)
Figure 67: Global Therapeutic Monoclonal Antibodies Market, By Infectious organism, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 68: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 69: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 70: Global Therapeutic Monoclonal Antibodies Market, By Other Targets, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 71: Global Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2021, 2023-2028 (%)
Figure 72: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 73: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 74: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Million)
Figure 75: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Million)
Figure 76: Global Therapeutic Monoclonal Antibodies Market, By Cancer, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 77: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 78: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 79: Global Therapeutic Monoclonal Antibodies Market, By Infectious Disease, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 80: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 81: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 82: Global Therapeutic Monoclonal Antibodies Market, By Autoimmune Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 83: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 84: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 85: Global Therapeutic Monoclonal Antibodies Market, By Neurological Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 86: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 87: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 88: Global Therapeutic Monoclonal Antibodies Market, By Other Indications, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 89: Global Therapeutic Monoclonal Antibodies Market CAGR, By Route of Administration, By Value, 2018-2021, 2023-2028 (%)
Figure 90: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2022,2028)
Figure 91: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2023-2028)
Figure 92: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Million)
Figure 93: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Million)
Figure 94: Global Therapeutic Monoclonal Antibodies Market, By Intravenous, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 95: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 96: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 97: Global Therapeutic Monoclonal Antibodies Market, By Subcutaneous, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 98: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 99: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 100: Global Therapeutic Monoclonal Antibodies Market, By Other ROA, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 101: Market Value of the Americas is expected to grow from USD 88.15 Bn to USD 467.69 Billion in 2028
Figure 102: Americas Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of 379.54 during 2018-2028
Figure 103: Market Value by Source
Figure 104: Market Value by Target
Figure 105: Top 2 Countries of Therapeutic Monoclonal Antibodies Market in Americas
Figure 106: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 107: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 108: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 109: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 110: Americas Therapeutic Monoclonal Antibodies Market Share, By Source, 2021 (%)
Figure 111: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 112: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 113: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 114: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 115: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 116: Americas Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 117: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 118: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 119: Americas Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 120: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 121: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 122: Americas Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 123: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 124: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 125: Americas Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 126: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 127: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 128: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 129: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 130: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Figure 131: Americas Cell surface antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 132: Americas Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or drug, By Value, 2018-2021 (USD Billion)
Figure 133: Americas Therapeutic Monoclonal Antibodies Market Size, Plasma protein or drug, By Value, 2022-2028 (USD Billion)
Figure 134: Americas Plasma protein or drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 135: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2018-2021 (USD Billion)
Figure 136: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2022-2028 (USD Billion)
Figure 137: Americas Infectious organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 138: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 139: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 140: Americas Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 141: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 142: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 143: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 144: Americas Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 145: Americas Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 146: Americas Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 147: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 148: Americas Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 149: Americas Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 150: Americas Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 151: Americas Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 152: Americas Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 153: Americas Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 154: Americas Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 155: Americas Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 156: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 157: Americas Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 158: Americas Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 159: Americas Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 160: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 161: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 162: Americas Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 163: Americas Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 164: Americas Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 165: Americas Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 166: Americas Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 167: Americas Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 168: Americas Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 169: Americas Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 170: Americas Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 171: United States Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 172: United States Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 173: United States Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 174: United States Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 175: United States Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 176: United States Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 177: United States Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 178: Canada Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 179: Canada Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 180: Canada Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 181: Canada Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 182: Canada Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 183: Canada Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 184: Canada Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 185: Rest of Americas Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 186: Rest of Americas Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 187: Rest of Americas Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 188: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 189: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 190: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 191: Rest of Americas Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 192: Market Value of the Europe is expected to grow from USD 79.76 Bn to USD 313.41 Billion in 2028
Figure 193: Europe Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of 233.65 Mn Units during 2018-2028
Figure 194: Market Value by Target
Figure 195: Market Value by Source
Figure 196: Top 3 Countries of Therapeutic Monoclonal Antibodies
Figure 197: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 198: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 199: Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 200: Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 201: Europe Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 202: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 203: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 204: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 205: Europe Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 206: Europe Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 207: Europe Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 208: Europe Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 209: Europe Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 210: Europe Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 211: Europe Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 212: Europe Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 213: Europe Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 214: Europe Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 215: Europe Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 216: Europe Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 217: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 218: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 219: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 220: Europe Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2018-2021 (USD Billion)
Figure 221: Europe Therapeutic Monoclonal Antibodies Market Size, By Cell Surface Antigen, By Value, 2022-2028 (USD Billion)
Figure 222: Europe Cell Surface Antigen Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 223: Europe Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2018-2021 (USD Billion)
Figure 224: Europe Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or Drug, By Value, 2022-2028 (USD Billion)
Figure 225: Europe Plasma protein or Drug Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 226: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2018-2021 (USD Billion)
Figure 227: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Organism, By Value, 2022-2028 (USD Billion)
Figure 228: Europe Infectious Organism Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 229: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 230: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 231: Europe Other Targets Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 232: Europe Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2022, 2023-2028 (%)
Figure 233: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 234: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 235: Europe Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Billion)
Figure 236: Europe Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Billion)
Figure 237: Europe Cancer Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 238: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 239: Europe Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 240: Europe Infectious Disease Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 241: Europe Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 242: Europe Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 243: Europe Autoimmune Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 244: Europe Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 245: Europe Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 246: Europe Neurological Disorders Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 247: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 248: Europe Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 249: Europe Other Indications Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 250: Europe Therapeutic Monoclonal Antibodies Market CAGR, By ROA, By Value, 2018-2021, 2023-2028 (%)
Figure 251: Basis Point Analysis of Europe Therapeutic Monoclonal Antibodies Market, By ROA (2022,2028)
Figure 252: Market Opportunity Analysis of Europe Therapeutic Monoclonal Antibodies Market, By ROA (2023-2028)
Figure 253: Europe Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Billion)
Figure 254: Europe Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Billion)
Figure 255: Europe Intravenous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 256: Europe Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 257: Europe Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 258: Europe Subcutaneous Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 259: Europe Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 260: Europe Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 261: Europe Other ROA Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 262: Germany Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 263: Germany Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 264: Germany Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 265: Germany Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 266: Germany Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 267: Germany Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 268: Germany Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 269: United Kingdom Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 270: United Kingdom Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 271: United Kingdom Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 272: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 273: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 274: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 275: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 276: France Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 277: France Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 278: France Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 279: France Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 280: France Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 281: France Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 282: France Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 283: Italy Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 270: United Kingdom Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 271: United Kingdom Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 272: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 273: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 274: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 275: United Kingdom Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 276: France Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 277: France Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 278: France Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 279: France Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 280: France Therapeutic Monoclonal Antibodies Market Share, By Target, By Value, 2021 (%)
Figure 281: France Therapeutic Monoclonal Antibodies Market Share, By Indication, By Value, 2021 (%)
Figure 282: France Therapeutic Monoclonal Antibodies Market Share, By ROA, By Value, 2021 (%)
Figure 283: Italy Therapeutic Monoclonal Antibodies Market, By Value, 2018-2028 (USD Billion)
Figure 284: Italy Therapeutic Monoclonal Antibodies Market, CAGR, By Value, 2018-2021, 2023-2028 (%)
Figure 285: Italy Therapeutic Monoclonal Antibodies Market Value, By Source, 2021 (USD Million)
Figure 286: Italy Therapeutic Monoclonal Antibodies Market Share, By Source, By Value, 2021 (%)
Figure 287: Italy Therapeutic Monoclonal Antibodies Market Share, By Tar